{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T14:21:53Z","timestamp":1774794113059,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.antiviral.2012.02.001","type":"journal-article","created":{"date-parts":[[2012,2,15]],"date-time":"2012-02-15T16:32:13Z","timestamp":1329323533000},"page":"1-8","source":"Crossref","is-referenced-by-count":26,"title":["A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129\/17D-204 peripheral challenge mouse model"],"prefix":"10.1016","volume":"94","author":[{"given":"Brett A.","family":"Thibodeaux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina C.","family":"Garbino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan M.","family":"Liss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Piper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob J.","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol D.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T.","family":"Roehrig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2012.02.001_b0005","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1086\/511869","article-title":"Yellow fever: epidemiology and prevention","volume":"44","author":"Barnett","year":"2007","journal-title":"Clin. Infect. Dis."},{"issue":"Pt 11","key":"10.1016\/j.antiviral.2012.02.001_b0010","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1099\/0022-1317-67-11-2539","article-title":"Antibody-mediated early death in vivo after infection with yellow fever virus","volume":"67","author":"Barrett","year":"1986","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2012.02.001_b0015","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1016\/j.vaccine.2008.06.025","article-title":"International laboratory network for yellow fever vaccine-associated adverse events","volume":"26","author":"Barrett","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2012.02.001_b0020","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.coi.2009.05.018","article-title":"Yellow fever vaccine \u2013 how does it work and why do rare cases of serious adverse events take place?","volume":"21","author":"Barrett","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.antiviral.2012.02.001_b0025","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1128\/AAC.01178-09","article-title":"Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus","volume":"54","author":"Beigel","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Pt 2","key":"10.1016\/j.antiviral.2012.02.001_b0305","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1099\/0022-1317-67-2-229","article-title":"Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses.","volume":"67","author":"Brandriss","year":"1986","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2012.02.001_b0320","first-page":"1","article-title":"Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002","volume":"51","author":"Cetron","year":"2002","journal-title":"MMWR Recomm. Rep."},{"key":"10.1016\/j.antiviral.2012.02.001_b0040","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1084\/jem.20031223","article-title":"A critical role for induced IgM in the protection against West Nile virus infection","volume":"198","author":"Diamond","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2012.02.001_b0045","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcv.2006.02.005","article-title":"Yellow fever vaccine-associated viscerotropic disease and death in Spain","volume":"36","author":"Doblas","year":"2006","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2012.02.001_b0050","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.vaccine.2006.01.009","article-title":"Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil","volume":"24","author":"Engel","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2012.02.001_b0055","doi-asserted-by":"crossref","first-page":"8236","DOI":"10.1016\/j.vaccine.2010.10.070","article-title":"WHO Working Group on Technical Specifications for manufacture and evaluation of yellow fever Vaccines, Geneva, Switzerland, 13\u201314 May 2009","volume":"28","author":"Ferguson","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2012.02.001_b0060","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.2146\/ajhp050514","article-title":"Treatment of rheumatoid arthritis","volume":"63","author":"Gaffo","year":"2006","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.antiviral.2012.02.001_b0065","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cll.2010.01.001","article-title":"Yellow fever: a reemerging threat","volume":"30","author":"Gardner","year":"2010","journal-title":"Clin. Lab. Med."},{"issue":"Pt 6","key":"10.1016\/j.antiviral.2012.02.001_b0070","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1099\/0022-1317-70-6-1605","article-title":"Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence","volume":"70","author":"Gould","year":"1989","journal-title":"J. Gen. Virol."},{"issue":"Pt 12","key":"10.1016\/j.antiviral.2012.02.001_b0075","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1099\/0022-1317-68-12-3105","article-title":"Immune enhancement of yellow fever virus neurovirulence for mice. Studies of mechanisms involved","volume":"68","author":"Gould","year":"1987","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2012.02.001_b0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1749-6632.2001.tb02681.x","article-title":"Human arbovirus infections worldwide","volume":"951","author":"Gubler","year":"2001","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.antiviral.2012.02.001_b0085","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0188-4409(02)00378-8","article-title":"The global emergence\/resurgence of arboviral diseases as public health problems","volume":"33","author":"Gubler","year":"2002","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.antiviral.2012.02.001_b0090","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1128\/JCM.36.5.1277-1284.1998","article-title":"Recombinant mouse-human chimeric antibodies as calibrators in immunoassays that measure antibodies to Toxoplasma gondii","volume":"36","author":"Hackett","year":"1998","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2012.02.001_b0095","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.virol.2011.03.016","article-title":"Treatment of mice with human monoclonal antibody 24h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection","volume":"414","author":"Hunt","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2012.02.001_b0100","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1099\/vir.0.81925-0","article-title":"A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus","volume":"87","author":"Hunt","year":"2006","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2012.02.001_b0105","doi-asserted-by":"crossref","first-page":"e739","DOI":"10.1371\/journal.pntd.0000739","article-title":"The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity","volume":"4","author":"Hunt","year":"2010","journal-title":"PLoS neglected tropical diseases"},{"key":"10.1016\/j.antiviral.2012.02.001_b0110","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1128\/JCM.38.5.1827-1831.2000","article-title":"Detection of anti-arboviral immunoglobulin G by using a monoclonal antibody-based capture enzyme-linked immunosorbent assay","volume":"38","author":"Johnson","year":"2000","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2012.02.001_b0115","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1128\/JVI.73.1.783-786.1999","article-title":"New mouse model for dengue virus vaccine testing","volume":"73","author":"Johnson","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.02.001_b0120","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/nar\/28.1.214","article-title":"Kabat database and its applications: 30years after the first variability plot","volume":"28","author":"Johnson","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2012.02.001_b0125","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.antiviral.2006.08.008","article-title":"Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model","volume":"73","author":"Julander","year":"2007","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2012.02.001_b0130","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.vaccine.2005.01.089","article-title":"Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events","volume":"23","author":"Khromava","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2012.02.001_b0135","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1128\/JVI.02509-07","article-title":"E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence","volume":"82","author":"Lee","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.02.001_b0140","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001622-199811000-00012","article-title":"Use of rituximab, the new FDA-approved antibody","volume":"10","author":"Leget","year":"1998","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.antiviral.2012.02.001_b0145","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/0042-6822(87)90141-3","article-title":"Location of a neutralization determinant in the E protein of yellow fever virus (17D vaccine strain)","volume":"161","author":"Lobigs","year":"1987","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2012.02.001_b0150","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/TP.0b013e318186b8a3","article-title":"Basiliximab versus steroids in double therapy immunosuppression in liver transplantation: a prospective randomized clinical trial","volume":"86","author":"Lupo","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2012.02.001_b0155","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3201\/eid0706.010605","article-title":"Advanced age a risk factor for illness temporally associated with yellow fever vaccination","volume":"7","author":"Martin","year":"2001","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2012.02.001_b0160","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1016\/j.vaccine.2005.03.002","article-title":"Yellow fever vaccination: how much is enough?","volume":"23","author":"Massad","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2012.02.001_b0165","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.4049\/jimmunol.132.3.1533","article-title":"Elucidation of the topography and determination of the protective epitopes on the E glycoprotein of Saint Louis encephalitis virus by passive transfer with monoclonal antibodies","volume":"132","author":"Mathews","year":"1984","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2012.02.001_b0170","doi-asserted-by":"crossref","first-page":"e1000614","DOI":"10.1371\/journal.ppat.1000614","article-title":"A mouse model for studying viscerotropic disease caused by yellow fever virus infection","volume":"5","author":"Meier","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2012.02.001_b0175","first-page":"341","article-title":"Yellow fever as an endemic\/epidemic disease and priorities for vaccination","volume":"99","author":"Monath","year":"2006","journal-title":"Bull. Soc. Pathol. Exot."},{"key":"10.1016\/j.antiviral.2012.02.001_b0180","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.antiviral.2007.10.009","article-title":"Treatment of yellow fever","volume":"78","author":"Monath","year":"2008","journal-title":"Antiviral. Res."},{"key":"10.1016\/j.antiviral.2012.02.001_b0185","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4161\/hv.1.5.2221","article-title":"Yellow fever 17D vaccine safety and immunogenicity in the elderly","volume":"1","author":"Monath","year":"2005","journal-title":"Hum. Vaccin."},{"key":"10.1016\/j.antiviral.2012.02.001_b0190","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1086\/508293","article-title":"Humanized monoclonal antibody against West Nile Virus envelope protein administered after neuronal Infection protects against lethal encephalitis in hamsters","volume":"194","author":"Morrey","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2012.02.001_b0195","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1128\/AAC.00147-07","article-title":"Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model","volume":"51","author":"Morrey","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.02.001_b0200","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/13550280801958930","article-title":"West Nile virus-induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons","volume":"14","author":"Morrey","year":"2008","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.antiviral.2012.02.001_b0205","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nature03956","article-title":"Structural basis of West Nile virus neutralization by a therapeutic antibody","volume":"437","author":"Nybakken","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2012.02.001_b0210","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nm1240","article-title":"Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus","volume":"11","author":"Oliphant","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2012.02.001_b0215","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0042-6822(80)90481-X","article-title":"Isolation and characterization of hybrid cell lines producing monoclonal antibodies directed against the structural proteins of Sindbis virus","volume":"101","author":"Roehrig","year":"1980","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2012.02.001_b0315","doi-asserted-by":"crossref","DOI":"10.1089\/vim.2008.0007","article-title":"Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses","author":"Roehrig","year":"2008","journal-title":"Viral Immunol."},{"key":"10.1016\/j.antiviral.2012.02.001_b0225","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1749-6632.2001.tb02704.x","article-title":"Antibody prophylaxis and therapy for flavivirus encephalitis infections","volume":"951","author":"Roehrig","year":"2001","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.antiviral.2012.02.001_b0230","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4269\/ajtmh.2004.71.306","article-title":"Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease","volume":"71","author":"Sbrana","year":"2004","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2012.02.001_b0235","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.4269\/ajtmh.2006.74.1084","article-title":"Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus) III. Clinical laboratory values","volume":"74","author":"Sbrana","year":"2006","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2012.02.001_b0240","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/jmv.1890080204","article-title":"Antibody-mediated infection of macrophages and macrophage-like cell lines with 17D-yellow fever virus","volume":"8","author":"Schlesinger","year":"1981","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2012.02.001_b0245","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1128\/JVI.60.3.1153-1155.1986","article-title":"Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1","volume":"60","author":"Schlesinger","year":"1986","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.02.001_b0250","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0042-6822(83)90059-4","article-title":"Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein","volume":"125","author":"Schlesinger","year":"1983","journal-title":"Virology"},{"issue":"Pt 1","key":"10.1016\/j.antiviral.2012.02.001_b0255","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1099\/0022-1317-76-1-217","article-title":"Neutralizing F(ab\u2032)2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis","volume":"76","author":"Schlesinger","year":"1995","journal-title":"J. Gen. Virol."},{"issue":"Pt 10","key":"10.1016\/j.antiviral.2012.02.001_b0260","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1099\/0022-1317-65-10-1637","article-title":"Analysis of 17D yellow fever virus envelope protein epitopes using monoclonal antibodies","volume":"65","author":"Schlesinger","year":"1984","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2012.02.001_b0265","first-page":"1","article-title":"Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Staples","year":"2010","journal-title":"MMWR Recomm. Rep."},{"key":"10.1016\/j.antiviral.2012.02.001_b0270","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1086\/320199","article-title":"Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies","volume":"183","author":"Tesh","year":"2001","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2012.02.001_b0295","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1128\/CVI.05269-11","article-title":"Development of a human-murine chimeric immunoglobulin M for use in the serological detection of human alphavirus antibodies","volume":"18","author":"Thibodeaux","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.antiviral.2012.02.001_b0300","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1128\/CVI.00097-10","article-title":"Development of human-murine chimeric immunoglobulin G for use in the serological detection of human flavivirus and alphavirus antibodies","volume":"17","author":"Thibodeaux","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.antiviral.2012.02.001_b0285","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1128\/CVI.00354-08","article-title":"Development of a human-murine chimeric immunoglobulin M antibody for use in the serological detection of human flavivirus antibodies","volume":"16","author":"Thibodeaux","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.antiviral.2012.02.001_b0290","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1086\/320200","article-title":"Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology","volume":"183","author":"Xiao","year":"2001","journal-title":"J. Infect. Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354212000344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354212000344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T18:47:04Z","timestamp":1686768424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354212000344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0166354212000344"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2012.02.001","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}